May 08, 2025 marks National Amyloidosis Day, a time to place a spotlight on a rare but impactful condition that affects thousands of lives. At TwelveStone Health Partners, we’re proud to stand at the forefront of supporting patients with amyloidosis through our specialized infusion services. But what exactly is amyloidosis, and how do infusion therapies play a crucial role in managing this complex disease? Let’s explore the connection and why our commitment to personalized care matters.
Understanding Amyloidosis: A Hidden Challenge
Amyloidosis is a group of rare disorders characterized by the buildup of abnormal proteins, called amyloid fibrils, in tissues and organs. These proteins can accumulate in places like the heart, kidneys, liver, or nervous system, disrupting normal function and leading to a wide range of symptoms—fatigue, swelling, shortness of breath, or nerve pain, to name a few. The condition varies widely, with types like AL (light chain) amyloidosis, ATTR (transthyretin) amyloidosis, and AA (secondary) amyloidosis each presenting unique challenges.
For many, amyloidosis goes undiagnosed for years because its symptoms mimic more common conditions. National Amyloidosis Day is a call to action—raising awareness so patients can seek timely diagnosis and treatment. At TwelveStone, we see firsthand how early intervention can make a difference, and infusion therapy is often a cornerstone of that care.
Infusion Services: A Lifeline for Amyloidosis Patients
Infusion therapy is an approach that can target the root causes of the condition or alleviate its symptoms, depending on the type and stage of amyloidosis.
- AL Amyloidosis: This type, linked to abnormal plasma cells in the bone marrow, often requires treatments like those for multiple myeloma. Chemotherapy drugs, such as bortezomib or daratumumab, can be administered via infusion to reduce the production of harmful light chain proteins. At 12Stone, our infusion centers provide a comfortable, expert-led environment for these critical therapies, ensuring patients receive the right dose at the right time.
- ATTR Amyloidosis: For patients with transthyretin amyloidosis, infusion therapies like patisiran—a groundbreaking RNA interference drug—work by silencing the gene responsible for producing faulty transthyretin proteins. This can slow amyloid buildup, particularly in the heart or nerves. Our team at 12Stone is equipped to handle these advanced treatments, offering hope to those with hereditary or wild-type ATTR.
- Supportive Care: Beyond targeting amyloid production, infusion services can deliver supportive medications—like diuretics for heart-related swelling or pain management drugs—helping patients maintain quality of life. Our home infusion options bring this care directly to patients, reducing the burden of travel during a challenging time.
Why TwelveStone Health Partners?
We are more than just a provider—we’re a partner in your chronic care journey. Our infusion services are designed with amyloidosis patients in mind, offering:
- Expertise: Our clinicians are trained in the nuances of rare diseases, ensuring precise administration and monitoring.
- Convenience: With multiple infusion centers and home-based options, we meet patients where they are—literally and figuratively.
- Compassion: We understand the emotional and physical toll of amyloidosis, and our team is here to support you every step of the way.
National Amyloidosis Day reminds us that awareness is the first step, but access to specialized care is what changes lives. Infusion therapy isn’t a cure, but it’s a vital tool in slowing disease progression and improving outcomes. Recent advances in treatments—like monoclonal antibodies and gene-silencing drugs—underscore how far we’ve come, and we take pride in bringing these innovations to our patients.
Have questions about how infusion therapy can help with amyloidosis?
Contact us today or call 844-893-0012 for more information. Let’s navigate this journey together.
